 |
 | |
 |  |
| We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level. |
The ticker is currently IVPH.OB, but let's hope it changes and the "OB" goes bye bye. The company caught my attention when Biomaven mentioned it and put up a press release in the Valuation thread. Pipeline page...... innovivepharma.com Management team...... Steven Kelly, President & CEO Steven Kelly brings more than fifteen years experience in a variety of commercial roles in biotechnology and pharmaceutical companies. Prior to joining Innovive, Mr. Kelly headed the newly created oncology marketing group for Sanofi-Synthelabo’s US division, where he led the launch of Eloxatin™, the pharmaceutical industry’s most successful anti-cancer product launch to date. Mr. Kelly joined Sanofi from IDEC Pharmaceuticals, where, in a co-promotion agreement with Genentech, he led the launch of Rituxan®, now one of the leading anticancer therapies in the U.S. Prior to IDEC, Mr. Kelly worked at Amgen, where he held various positions, including roles in Epogen® marketing, new products marketing, and manufacturing. Mr. Kelly holds an MBA from Cornell University and a BS, Biology and Chemistry from the University of Oregon. Adam Craig, M.D., Ph.D., Vice President & Chief Medical Officer Prior to joining Innovive, Dr. Craig was Medical Director and Vice President, Clinical Development for ArQule, Inc., where he established the company’s Clinical Development department and expanded its ability to conduct multiple clinical studies. He was a member of ArQule’s Executive Team. Before ArQule, Dr. Craig was Senior Director, Clinical Development for Ilex Oncology, Inc., where he helped gain the first approval of a pediatric chemotherapeutic agent in nearly a decade. Dr. Craig also served as Medical Advisor, Oncology for Antisoma plc (London, U.K). Dr. Craig holds Bachelor of Medicine and Bachelor of Surgery degrees from Charing Cross and Westminster Medical School, University of London, with prizes awarded in Oncology and Pediatrics. He earned his PhD in Molecular Medicine at the University of Leeds during a Medical Research Council Clinical Fellowship. Additionally, Dr. Craig holds an MBA from the Open University Business School. He is a member of the Royal College of Paediatrics and Child Health, the Royal College of Physicians of the United Kingdom, the American Society of Clinical Oncology, and the American Society of Hematology. Dr. Craig has authored or co-authored numerous journal articles and abstracts on oncology, including a medical textbook. J. Gregory Jester, Vice President & Chief Financial Officer Mr. Jester joined Innovive in October 2006 as Vice President and Chief Financial Officer. Prior to joining Innovive, from 1995 to 2006, Mr. Jester was employed by Barr Pharmaceuticals, Inc. most recently as Vice President and Corporate Controller where he led a 40 person team responsible for corporate and operational accounting, financial reporting and analysis, budgeting and forecasting as well as all SEC filings. Prior to Barr, Mr. Jester held various positions at Meridian Sports Inc., The CIT Group/Credit Finance and KPMG LLP. Mr. Jester is a Certified Public Accountant and received his B.S., Business Administration from the University of Richmond. Eric E. Poma, Ph.D., Vice President of Business Development Dr. Poma most recently served as Assistant Vice President, Business Development for ImClone Systems, Inc., where he was responsible for all licensing and partnership agreements. Dr. Poma also ran the Strategic Planning group at ImClone prior to his appointment to Business Development. Prior to Imclone, Dr. Poma was a Healthcare and Biotechnology analyst for Eagle Growth Investors and held a variety of positions at Bates Healthworld (marketing and contract sales), Rood Research (market research) and Cline, Davis & Mann (pharmaceutical advertising). Eric Poma earned his PhD in Microbiology and Immunology from the University of North Carolina at Chapel Hill, School of Medicine. He holds an MBA from the Leonard N. Stern School of Business at New York University and a Bachelor of Science in Biology from the University of North Carolina at Chapel Hill. | ||||||||||||||
|
| Home | Hot | SubjectMarks | PeopleMarks | Keepers | Settings |
| Terms Of Use | Contact Us | Copyright/IP Policy | Privacy Policy | About Us | FAQ | Advertise on SI |
| © 2025 Knight Sac Media. Data provided by Twelve Data, Alpha Vantage, and CityFALCON News |